Online:
Visits:
Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Chimeric Antigen Receptor (CAR) T cell Immunotherapy – Competitive Landscape, Pipeline and Market Analysis, 2017

Monday, February 13, 2017 23:14
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Publisher’s, “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Pipeline and Market Analysis, 2017″, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Chimeric Antigen Receptor (CAR) T cell Immunotherapy. This report provides information on the therapeutic development based on Chimeric Antigen Receptor (CAR) T cell Immunotherapy mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. Publisher’s Report also assesses the Chimeric Antigen Receptor (CAR) T cell Immunotherapy therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.

For more information about this report: http://www.reportsweb.com/chimeric-antigen-receptor-car-t-cell-immunotherapy-2017

Report Scope
- The report provides competitive pipeline landscape of Chimeric Antigen Receptor (CAR) T cell Immunotherapy
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy and also provide company profiling
- The report also gives the information of dormant pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001608703/sample

Reasons to Buy
- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Complete MOA intelligence and complete understanding over therapeutics development for Chimeric Antigen Receptor (CAR) T cell Immunotherapy
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Chimeric Antigen Receptor (CAR) T cell Immunotherapy pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

 

Table of Contents

Report Introduction
Executive Summary Snapshot
Executive Summary
Introduction
Chimeric antigen receptor (CAR) T-cells
History
CARs and Generations
Advantages of CAR-T cells
Adverse Events with CAR T-cell Therapy
Limitations of Existing Technologies for CAR T-Cells
CAR-T Cell Therapy-Analysis
CAR-T Collaboration Deals
CAR-T Cells Therapy Collaborations and Deal Year
Collaborations & Deal Value Trends
Companies collaborations for future developments
CAR-T Acquisitions Deals
CAR-T Cells Therapy Acquisitions Trends
CAR-T Cells Therapy Acquisitions Offerings by Big Giants
New facilityfor the development of CAR-T cells
JCAR015: Major Set Back for Juno Therapeutics
CAR-T Licensing Opportunities
Pipeline Scenario
Pipeline Products under Development-An Overview
Pipeline Products under Development by Company
CAR T-cells Therapeutic Areas & Companies
CAR-T cells Targeted Antigens
CAR-T Therapies-Clinical trials & Completion Year
CAR T-cell Technologies & Companies Involved
CAR-T Safety Switches & Company involved
Companies with Upcoming CAR-T Therapeutics
Pipeline Profiles
Other Active Companies
Miltenyi Biotec
ZMKS International Cancer Therapies Biotechnologies Co. Ltd.
Upcoming Technologies Better than CARs
Market Drivers
Market Barriers
SWOT Analysis
Report Methodology
Consulting Services

Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001608703/buying

Contact Us:

Call: +1-646-491-9876
Email: [email protected]

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.